Alector’s (ALEC) “Overweight” Rating Reiterated at Cantor Fitzgerald

Alector (NASDAQ:ALEC)‘s stock had its “overweight” rating reiterated by Cantor Fitzgerald in a research report issued to clients and investors on Monday, Benzinga reports.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $35.00 price target on shares of Alector in a research note on Thursday, June 20th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $14.67.

Alector Trading Up 2.7 %

NASDAQ:ALEC traded up $0.13 on Monday, hitting $4.98. The company had a trading volume of 101,548 shares, compared to its average volume of 626,259. The stock has a market capitalization of $484.65 million, a price-to-earnings ratio of -3.62 and a beta of 0.68. The firm has a 50 day moving average of $5.31 and a two-hundred day moving average of $5.44. Alector has a 52 week low of $3.66 and a 52 week high of $8.90.

Alector (NASDAQ:ALEC) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.09. The firm had revenue of $15.08 million during the quarter, compared to the consensus estimate of $16.04 million. Alector had a negative net margin of 290.66% and a negative return on equity of 102.63%. During the same quarter last year, the firm earned $0.02 earnings per share. As a group, equities analysts forecast that Alector will post -1.92 EPS for the current year.

Insider Transactions at Alector

In other Alector news, CEO Arnon Rosenthal sold 26,499 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $4.88, for a total value of $129,315.12. Following the completion of the sale, the chief executive officer now directly owns 1,948,746 shares in the company, valued at $9,509,880.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Alector news, CEO Arnon Rosenthal sold 26,499 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $4.88, for a total value of $129,315.12. Following the completion of the sale, the chief executive officer now directly owns 1,948,746 shares in the company, valued at $9,509,880.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Marc Grasso sold 7,297 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $4.88, for a total transaction of $35,609.36. Following the completion of the sale, the chief financial officer now owns 130,740 shares of the company’s stock, valued at $638,011.20. The disclosure for this sale can be found here. Insiders sold a total of 58,222 shares of company stock worth $286,013 over the last three months. 9.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Alector

A number of large investors have recently bought and sold shares of ALEC. Federated Hermes Inc. lifted its stake in shares of Alector by 4.1% in the second quarter. Federated Hermes Inc. now owns 68,538 shares of the company’s stock valued at $311,000 after buying an additional 2,709 shares in the last quarter. Susquehanna Fundamental Investments LLC lifted its stake in shares of Alector by 2.8% in the second quarter. Susquehanna Fundamental Investments LLC now owns 129,664 shares of the company’s stock valued at $589,000 after buying an additional 3,500 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its stake in shares of Alector by 3.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 112,920 shares of the company’s stock valued at $513,000 after buying an additional 3,790 shares in the last quarter. ProShare Advisors LLC lifted its stake in shares of Alector by 24.1% in the first quarter. ProShare Advisors LLC now owns 19,709 shares of the company’s stock valued at $119,000 after buying an additional 3,827 shares in the last quarter. Finally, American International Group Inc. lifted its stake in shares of Alector by 13.0% in the first quarter. American International Group Inc. now owns 35,655 shares of the company’s stock valued at $215,000 after buying an additional 4,105 shares in the last quarter. 85.83% of the stock is currently owned by institutional investors and hedge funds.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.